Literature DB >> 19719388

Large-scale production of high-quality helper-dependent adenoviral vectors using adherent cells in cell factories.

Masataka Suzuki1, Racel Cela, Christian Clarke, Terry K Bertin, Susana Mouriño, Brendan Lee.   

Abstract

The most efficient and widely used system for generating helper-dependent adenoviral vectors (HDAds) is the Cre/loxP system developed by Graham and co-workers (Parks, R.J., Chen, L., Anton, M., Sankar, U., Rudnicki, M.A., and Graham, F.L. [ 1996 ]. Proc. Natl. Acad. Sci. U. S. A. 93, 13565-13570). Alternative systems have been developed for HDAd production, but all are limited by the technical complexity of a three-component vector production system for reproducibly generating large quantities of adenovirus with high infectivity and low helper virus (HV) contamination. Recently, these problems were addressed by Ng and co-workers (Palmer, D., and Ng, P. [ 2003 ]. Mol Ther. 8, 846-852), who developed an improved system that combines the use of a suspension-adapted producer cell line expressing high levels of Cre recombinase, a HV resistant to mutation, and a refined purification protocol. With this system, >1 x 10(13) highly infectious vector particles are easily produced without vector genome rearrangements and having very low HV contamination levels. However, the Ng system incorporates a spinner flask culture system that involves considerable time, effort, and tissue culture medium to produce HDAds. We have an alternative system to obtain comparable quantities with equivalent quality to the spinner flask approach but requiring reduced labor and lower volumes of medium. This method utilizes a 10-chamber cell factory with adherent cells to produce high infectivity of HDAds with minimal HV contamination while improving yield and reducing technical complexity, effort, and medium requirements. This system is easily translatable to the production of clinical-grade HDAds for human trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19719388      PMCID: PMC2829450          DOI: 10.1089/hum.2009.096

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  18 in total

1.  Preparation of helper-dependent adenoviral vectors.

Authors:  Philip Ng; Robin J Parks; Frank L Graham
Journal:  Methods Mol Med       Date:  2002

2.  Construction of first-generation adenoviral vectors.

Authors:  Philip Ng; Frank L Graham
Journal:  Methods Mol Med       Date:  2002

3.  Optimization of the generation and propagation of gutless adenoviral vectors.

Authors:  Kiran Sakhuja; P Seshidhar Reddy; Shanthi Ganesh; Floro Cantaniag; Scott Pattison; Paullin Limbach; Dawn B Kayda; Michael J Kadan; Michael Kaleko; Sheila Connelly
Journal:  Hum Gene Ther       Date:  2003-02-10       Impact factor: 5.695

4.  Improved system for helper-dependent adenoviral vector production.

Authors:  Donna Palmer; Philip Ng
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

5.  Physical and infectious titers of helper-dependent adenoviral vectors: a method of direct comparison to the adenovirus reference material.

Authors:  Donna J Palmer; Philip Ng
Journal:  Mol Ther       Date:  2004-10       Impact factor: 11.454

Review 6.  Helper-dependent adenoviral vectors for gene therapy.

Authors:  Donna J Palmer; Philip Ng
Journal:  Hum Gene Ther       Date:  2005-01       Impact factor: 5.695

7.  A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal.

Authors:  R J Parks; L Chen; M Anton; U Sankar; M A Rudnicki; F L Graham
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

8.  Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.

Authors:  Brian D Brown; Chang Xin Shi; Sandra Powell; David Hurlbut; Frank L Graham; David Lillicrap
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

9.  Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates.

Authors:  Nicola Brunetti-Pierri; Donna J Palmer; Arthur L Beaudet; K Dee Carey; Milton Finegold; Philip Ng
Journal:  Hum Gene Ther       Date:  2004-01       Impact factor: 5.695

10.  A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia.

Authors:  Anja Ehrhardt; Hui Xu; Aaron M Dillow; Dwight A Bellinger; Timothy C Nichols; Mark A Kay
Journal:  Blood       Date:  2003-06-12       Impact factor: 22.113

View more
  25 in total

1.  NOD2 signaling contributes to the innate immune response against helper-dependent adenovirus vectors independently of MyD88 in vivo.

Authors:  Masataka Suzuki; Racel Cela; Terry K Bertin; Gautam Sule; Vincenzo Cerullo; John R Rodgers; Brendan Lee
Journal:  Hum Gene Ther       Date:  2011-07-08       Impact factor: 5.695

2.  Impact of adenovirus life cycle progression on the generation of canine helper-dependent vectors.

Authors:  P Fernandes; D Simão; M R Guerreiro; E J Kremer; A S Coroadinha; P M Alves
Journal:  Gene Ther       Date:  2014-10-23       Impact factor: 5.250

3.  Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis.

Authors:  Kyu Sang Joeng; Yi-Chien Lee; Joohyun Lim; Yuqing Chen; Ming-Ming Jiang; Elda Munivez; Catherine Ambrose; Brendan H Lee
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

4.  Restoration of the serum level of SERPINF1 does not correct the bone phenotype in Serpinf1 null mice.

Authors:  Abbhirami Rajagopal; Erica P Homan; Kyu Sang Joeng; Masataka Suzuki; Terry Bertin; Racel Cela; Elda Munivez; Brian Dawson; Ming-Ming Jiang; Frank Gannon; Susan Crawford; Brendan H Lee
Journal:  Mol Genet Metab       Date:  2015-12-02       Impact factor: 4.797

5.  A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics.

Authors:  Mariana Puntel; A K M G Muhammad; Marianela Candolfi; Alireza Salem; Kader Yagiz; Catherine Farrokhi; Kurt M Kroeger; Weidong Xiong; James F Curtin; Chunyan Liu; Niyati S Bondale; Jonathan Lerner; Robert N Pechnick; Donna Palmer; Philip Ng; Pedro R Lowenstein; Maria G Castro
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

6.  Helper-dependent adenovirus is superior to first-generation adenovirus for expressing transgenes in atherosclerosis-prone arteries.

Authors:  Bo Jiang; Kun Qian; Liang Du; Ian Luttrell; Kanchan Chitaley; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03-31       Impact factor: 8.311

7.  Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo.

Authors:  Masataka Suzuki; Terry K Bertin; Geoffrey L Rogers; Racel G Cela; Irene Zolotukhin; Donna J Palmer; Philip Ng; Roland W Herzog; Brendan Lee
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

8.  Capsid-modified adenoviral vectors for improved muscle-directed gene therapy.

Authors:  Kilian Guse; Masataka Suzuki; Gautam Sule; Terry K Bertin; Henna Tyynismaa; Sofia Ahola-Erkkilä; Donna Palmer; Anu Suomalainen; Philip Ng; Vincenzo Cerullo; Akseli Hemminki; Brendan Lee
Journal:  Hum Gene Ther       Date:  2012-08-13       Impact factor: 5.695

9.  Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.

Authors:  Caroline E Porter; Amanda Rosewell Shaw; Youngrock Jung; Tiffany Yip; Patricia D Castro; Vlad C Sandulache; Andrew Sikora; Stephen Gottschalk; Michael M Ittman; Malcolm K Brenner; Masataka Suzuki
Journal:  Mol Ther       Date:  2020-02-24       Impact factor: 11.454

10.  Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.

Authors:  Amanda Rosewell Shaw; Caroline E Porter; Norihiro Watanabe; Kiyonori Tanoue; Andrew Sikora; Stephen Gottschalk; Malcolm K Brenner; Masataka Suzuki
Journal:  Mol Ther       Date:  2017-09-14       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.